Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 18/20 | 0.59 |
| ▸ | ACE | P12821 | 8/20 | 0.50 |
| ▸ | MMEL1 | Q495T6 | 2/20 | 0.46 |
| ▸ | EMG1 | Q92979 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18724833 | 1.00 | MME (0.59) | MMEACEMMEL1EMG1 | |
| SCHEMBL17011375 | 0.88 | MME (0.62) | MMEACEEMG1 | |
| SCHEMBL18724775 | 0.86 | MME (0.77) | MMEACE | |
| SCHEMBL9930524 | 0.86 | MME (0.77) | MMEACE | |
| SCHEMBL9929562 | 0.84 | MME (0.73) | MMEACE | |
| SCHEMBL14902429 | 0.82 | MME (0.72) | MMEACEMMEL1 | |
| SCHEMBL18597756 | 0.82 | MME (0.72) | MMEACEMMEL1 | |
| SCHEMBL19190564 | 0.82 | MME (0.58) | MMEACEMMEL1 | |
| SCHEMBL17011369 | 0.81 | MME (0.50) | MMEACE | |
| SCHEMBL18724763 | 0.81 | MME (0.50) | MMEACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11174219-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-11-16 | — | — | US | disclosed |
| US-20210155576-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-05-27 | — | — | US | disclosed |
| US-10829438-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-11-10 | — | — | US | disclosed |
| US-10315984-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-06-11 | — | — | US | disclosed |
| US-9884807-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-02-06 | — | — | US | disclosed |
| US-20170355664-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-12-14 | — | — | US | disclosed |
| EP-3199517-A1 | NEPRILYSIN INHIBITORS | Theravance Biopharma R&D IP, LLC (US) | 2017-08-02 | — | — | EP | disclosed |
| US-9670140-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-06-06 | — | — | US | disclosed |
| EP-2864292-B1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2017-04-12 | — | — | EP | disclosed |
| US-20160002148-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-01-07 | — | — | US | disclosed |
| US-9108934-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160002148-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | MME 1/4885ACE 3/4885MMEL1 307/4885 |
| US-11174219-B2 | Neprilysin inhibitors | MME, REN, ACE | MME 1/4885ACE 3/4885MMEL1 307/4885 |
| US-10829438-B2 | Neprilysin inhibitors | MME, REN, ACE | MME 1/4885ACE 3/4885MMEL1 307/4885 |
| US-20210155576-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | MME 1/4885ACE 3/4885MMEL1 307/4885 |
| US-10315984-B2 | Neprilysin inhibitors | MME, REN, ACE | MME 1/4885ACE 3/4885MMEL1 307/4885 |
| US-20170355664-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | MME 1/4885ACE 3/4885MMEL1 307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.